BioNTech Revenue vs. Cash And Equivalents
| BNTX Stock | USD 120.72 2.18 1.84% |
Total Revenue | First Reported 2018-06-30 | Previous Quarter 128.7 M | Current Value 1.2 B | Quarterly Volatility 2.2 B |
For BioNTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioNTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioNTech SE utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioNTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioNTech SE over time as well as its relative position and ranking within its peers.
BioNTech |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.227 | Earnings Share (2.04) | Revenue Per Share 12.618 | Quarterly Revenue Growth 0.39 | Return On Assets (0.01) |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioNTech SE Cash And Equivalents vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioNTech's current stock value. Our valuation model uses many indicators to compare BioNTech value to that of its competitors to determine the firm's financial worth. BioNTech SE is the top company in revenue category among its peers. It also is number one stock in cash and equivalents category among its peers creating about 2.44 of Cash And Equivalents per Revenue. At this time, BioNTech's Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNTech's earnings, one of the primary drivers of an investment's value.BioNTech Revenue vs. Competition
BioNTech SE is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 3.97 Billion. BioNTech totals roughly 3.82 Billion in revenue claiming about 96% of equities under Health Care industry.
BioNTech Cash And Equivalents vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
BioNTech |
| = | 3.82 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
BioNTech |
| = | 9.33 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
BioNTech Cash And Equivalents Comparison
BioNTech is currently under evaluation in cash and equivalents category among its peers.
BioNTech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioNTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioNTech will eventually generate negative long term returns. The profitability progress is the general direction of BioNTech's change in net profit over the period of time. It can combine multiple indicators of BioNTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 244.8 M | 232.6 M | |
| Net Interest Income | 349.7 M | 367.2 M | |
| Interest Income | 357.6 M | 375.5 M | |
| Operating Income | 690.4 M | 655.9 M | |
| Net Income From Continuing Ops | 930.3 M | 883.8 M | |
| Income Before Tax | 1.2 B | 1.1 B | |
| Total Other Income Expense Net | 495.7 M | 520.5 M | |
| Net Income Applicable To Common Shares | 11.8 B | 12.4 B | |
| Net Income | 1.2 B | 1.1 B | |
| Income Tax Expense | 255.8 M | 243 M | |
| Change To Netincome | 1.4 B | 1.5 B | |
| Net Income Per Share | 3.83 | 3.64 | |
| Income Quality | 4.53 | 4.76 | |
| Net Income Per E B T | 0.78 | 0.80 |
BioNTech Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioNTech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioNTech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioNTech's important profitability drivers and their relationship over time.
Use BioNTech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.BioNTech Pair Trading
BioNTech SE Pair Trading Analysis
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioNTech position
In addition to having BioNTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Market Neutral Funds Thematic Idea Now
Market Neutral Funds
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.